Seladelpar, a PPAR-δ agonist approved in 2024, is indicated for the treatment of primary biliary cholangitis (PBC) in patients who have an inadequate response to ursodeoxycholic acid (UDCA). The use of this drug must be strictly managed in accordance with prescriptions, and it is associated with risks such as fractures and abnormal liver function.

How to Purchase Seladelpar

Overseas Purchase

Patients may choose to consult and purchase seladelpar at hospital pharmacies or legitimate drugstores in countries or regions where the drug has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase Through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Seladelpar

Medication Contraindications and Risk Assessment

Absolute Contraindications: The drug is contraindicated in patients with decompensated cirrhosis (e.g., ascites, variceal bleeding); patients with complete biliary obstruction should avoid using it.

Special Populations: The safety of seladelpar in pregnant women, lactating women, and children has not been established, so a thorough assessment of the benefit-risk ratio is required.

Drug Specifications and Storage Requirements

Characteristics of Authentic Products: It is available as 10mg hard capsules, with contents being white to off-white powder. The drug should be stored in an environment at 20°C–25°C and protected from moisture.

Dosage Specifications: Only 10mg taken orally once daily is recommended; excessive dosage may cause elevated transaminases or muscle pain.

Combined Therapy and Drug Interactions

Combination with UDCA: 94% of patients need to use seladelpar in combination with UDCA, while 6% of patients who are intolerant to UDCA may receive monotherapy with seladelpar.

Contraindicated Concomitant Drugs: Concomitant use with OAT3 inhibitors (e.g., probenecid) and potent CYP2C9 inhibitors (e.g., fluconazole) should be avoided; when used with bile acid sequestrants, an interval of 4 hours between administrations is required.

Identification of Authentic vs. Counterfeit Seladelpar

Verification of Packaging and Labels

Anti-Counterfeiting Marks: The outer box of authentic products must include FDA approval information, batch number, and expiration date.

Inspection of Contents: The capsules should be free from damage and abnormal odors, and the sustained-release design should prevent rapid dissolution when exposed to water.

Verification of Channel Legitimacy

Reject Unauthorized Channels: Drugs from unknown online sources pose extremely high risks. The qualification of suppliers can be verified through the FDA Orange Book or the official website of Gilead (the manufacturer).

Vigilance Against Abnormally Low Prices: The production cost of seladelpar is relatively high, so products with significantly low prices may be counterfeit or expired.